469PSafety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti ‐PD‐L1 antibody, in patients (pts) with advanced cancers

ConclusionsCosibelimab has demonstrated a safe and well-tolerated safety profile with evidence of durable anti ‐tumor activity in several advanced cancers, and linear PK. Cosibelimab is being further evaluated in multiple tumor-specific expansion cohorts. Updated results will be presented.Clinical trial identificationNCT03212404.Legal entity responsible for the studyCheckpoint Therapeutics, Inc.FundingCheckpoint Therapeutics, Inc.DisclosureP.R. Clingan: Research grant / Funding (institution): Merck Sharp& Dohme Corp; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Bristol Myers; Research grant / Funding (institution): Checkpoint Therapeutics, Inc. A.M. Mant: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. G.E. Richardson: Research grant / Funding (institution): Novotech; Research grant / Funding (institution): Roche; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Alphapharm; Research grant / Funding (institution): Checkpoint Therapeutics. D.M. Kowalski: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. P. Koralewski: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. I. Lugowska: Research grant / Funding (institution): Checkpoint Therapeutics, Inc.; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research